- Home
- Find medicine
- Human medicines
- European public assessment reports
- Patient safety
- Pending EC decisions
- Withdrawn applications
- Paediatrics
- Rare disease designations
- Medicines under evaluation
- Medicines for use outside the EU
- Referrals
- Periodic safety update report single assessments
- Shortages catalogue
- Recommendations on medication errors
- Veterinary medicines
- Herbal medicines for human use
- Human medicines
- Human regulatory
- Pre-authorisation
- Post-opinion
- Post-authorisation
- Templates for assessors
- Templates for industry
- Dossier submission requirements
- Improving quality of submissions
- Post-authorisation procedural Q&A
- Article 5 procedure
- Variations regulation
- Type-IA variations
- Type-IB variations
- Type-II variations
- Extension applications
- Grouping of variations
- Worksharing
- Classification of changes
- Pre-submission queries service
- Changing the name of a medicinal product
- Annual re-assessment
- Post-authorisation measures
- Renewals
- Annual renewal of conditional marketing authorisations
- PASS
- PAES
- Article 46 paediatric study submission
- Risk management plan (RMP)
- PSURs
- Transfer of marketing authorisations
- Transparency
- Pharmacovigilance system
- Article 61(3) Notifications
- Withdrawals and cessation
- Marketing and cessation notification
- Sunset clause monitoring
- Urgent safety restrictions
- Other
- Certificates for products
- What we publish
- Product information
- Scientific advice and protocol assistance
- Support for early access
- Adaptive pathways
- Scientific guidelines
- Search guidelines
- Quality
- Q&A on quality
- Biologicals
- Non-clinical
- Clinical efficacy and safety
- Alimentary tract and metabolism
- Blood and blood-forming organs
- Blood products
- Cardiovascular system
- Dermatologicals
- Genitourinary system and sex hormones
- Anti-infectives for systemic use
- Antineoplastic and immunomodulating agents
- Rheumatology / musculoskeletal system
- Nervous system
- Respiratory system
- Radiopharmaceuticals and diagnostic agents
- Allergy/immunology
- Biostatistics
- General
- Clinical pharmacology and pharmacokinetics
- ICH
- Multidisciplinary
- Innovation Task Force
- Supporting SMEs
- Paediatric medicine
- Paediatric Regulation
- Workshops
- Research and development
- Marketing authorisation
- Post-authorisation
- Scientific guidelines: Paediatrics
- Geriatric medicine
- Orphan designation
- Herbal products
- Referral procedures
- Q&A: Urgent Union Procedures (Article 107i)
- Q&A: Article 13 referral procedures
- Q&A: Article 20 pharmacovigilance procedures
- Q&A: Article 20 non-pharmacovigilance procedures
- Q&A: Article 29(4) referral procedures
- Q&A: Article 30 referral procedures
- Q&A: Article 31 pharmacovigilance referrals
- Q&A: Article 31 non-pharmacovigilance referrals
- Guidance
- Article 58 applications
- Pharmacovigilance
- Background
- Pharmacovigilance legislation
- Medical literature monitoring
- Pharmacovigilance fees
- Good pharmacovigilance practices
- Medication errors
- Risk management
- Signal management
- Medicines under additional monitoring
- Post-authorisation safety studies
- Periodic safety update reports
- European Risk Management Strategy
- EudraVigilance
- Incident management plan
- Patient registries
- Guidance
- Data submission on medicines
- Advanced therapies
- Clinical trials
- Clinical data publication
- Inspections
- Falsified medicines
- Quality by design
- Product defects and recalls
- Parallel distribution
- Medicine shortages
- Antimicrobial resistance
- Non-pharmaceutical products
- Fees
- Medicines and emerging science
- Biological and chemical agents
- Veterinary regulatory
- Pre-authorisation
- Post-authorisation
- Certificates for products
- Post-authorisation procedural Q&A
- Article 5 procedure
- Type IA variations
- Type IB variations
- Type II variations
- Type II variations vs Extension applications
- Extension applications
- Grouping of variations
- Worksharing of variations
- Changing the (Invented) Name of a Centrally Authorised Medicinal Product
- Renewals
- Post-authorisation Measures (Recommendations, Conditions and Specific Obligations)
- Transfer
- PSURs
- Mock-ups
- Must a product be marketed after the Authorisation has been granted (“Sunset Clause”)?
- Transparency
- Other
- General guidance
- Product information
- Scientific advice
- Scientific guidelines
- Supporting SMEs
- Innovation Task Force
- Referral procedures
- Maximum residue limits
- Pharmacovigilance
- Inspections
- Quality by design
- Minor uses / minor species and limited markets
- Antimicrobial resistance
- Availability of veterinary vaccines
- Product defects and recalls
- Parallel distribution
- Legislative issues
- Fees
- Committees
- CHMP
- PRAC
- CVMP
- COMP
- HMPC
- CAT
- PDCO
- Working parties and other groups
- CHMP
- Biologics Working Party
- Patients' and Consumers' Working Party
- Healthcare Professionals' Working Party
- Quality Working Party
- Safety Working Party
- Scientific Advice Working Party
- Biosimilar Medicinal Products Working Party
- Biostatistics Working Party
- Blood Products Working Party
- Cardiovascular Working Party
- Central Nervous System Working Party
- Excipients Drafting Group
- Gastroenterology Drafting Group
- Infectious Diseases Working Party
- Inter-Committee Scientific Advisory Group on Oncology
- (Invented) Name Review Group
- Oncology Working Party
- Pharmacogenomics Working Party
- Pharmacokinetics Working Party
- Radio-pharmaceuticals Drafting Group
- Respiratory Drafting Group
- Rheumatology / Immunology Working Party
- Vaccines Working Party
- Scientific Advisory Group on Cardiovascular Issues
- Scientific Advisory Group on Anti-infectives
- Scientific Advisory Group on Diabetes / Endocrinology
- Scientific Advisory Group on HIV/Viral Diseases
- Scientific Advisory Group on Neurology
- Scientific Advisory Group on Psychiatry
- Scientific Advisory Group on Vaccines
- Working Group on Quality Review of Documents
- Expert Group on 3Rs
- Active Substance Master File Working Group
- Geriatric Expert Group
- SmPC Advisory Group
- Modelling and Simulation Working Group
- Coordination Group
- CVMP
- Antimicrobials Working Party
- Efficacy Working Party
- Environmental Risk Assessment Working Party
- Immunologicals Working Party
- Quality Working Party
- Pharmacovigilance Working Party
- Safety Working Party
- Scientific Advice Working Party
- Inter-Committee Scientific Advisory Group on Oncology
- Ad Hoc Expert Group on Veterinary Novel Therapies
- Working Group on Quality Review of Documents
- Expert Group on 3Rs
- Active Substance Master File Working Group
- COMP
- HMPC
- CAT
- PDCO
- CMDh
- CMDv
- EudraVigilance Expert Working Group
- CHMP
- News and Events
- Partners & Networks
- About Us
- What we do
- Who we are
- Management Board
- Executive Director
- Deputy Executive Director and support services
- Advisory functions
- Human Medicines Research and Development
- Human Medicines Evaluation
- Inspections, Human Medicines Pharmacovigilance and Committees
- Veterinary Medicines
- Stakeholders and Communication
- Information Management
- Administration and Corporate Management
- How we work
- European medicines regulatory network
- Conflicts of interests
- Anti-fraud strategy
- Transparency
- Access to documents
- Public hearings
- Governance and reporting
- Annual reports and work programmes
- Funding
- Financial management and budgetary reporting
- Policies and procedures
- Integrated management system
- Legal foundation
- History of EMA
- Careers
- Procurement
- Support to research
- Contact
- Legal
- About this website
- FAQs
- Find medicine
Send a question | About this website | Legal | Privacy | Complaints | Contacts | FAQs | Business hours and holidays | Glossary | Site map | 
30 Churchill Place, Canary Wharf, London E14 5EU, United Kingdom . Tel. +44 (0)20 3660 6000 . Fax +44 (0)20 3660 5555